Elsevier

Immunology Letters

Volume 197, May 2018, Pages 70-77
Immunology Letters

Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review

https://doi.org/10.1016/j.imlet.2018.03.006Get rights and content

Highlights

  • Live bacteria can be engineered to deliver target antigen to excite the host immune system.

  • The form of heterologous antigen expression has a crucial impact on the type and efficiency of immune response.

  • The selection of an effective protective antigen is a vital factor for developing live-vector vaccine.

Abstract

Live bacteria, including attenuated bacteria and probiotics, can be engineered to deliver target antigen to excite the host immune system. The preponderance of these live bacterial vaccine vectors is that they can stimulate durable humoral and cellular immunity. Moreover, delivery strategies of heterologous antigen in live bacterial promote the applications of new vaccine development. Genetic technologies are evolving, which potentiate the developing of heterologous antigen delivery systems, including bacterial surface display system, bacterial secretion system and balanced lethal vector system. Although the live bacterial vaccine vector is a powerful adjuvant, certain disadvantages, such as safety risk, must also be taken into account. In this review, we compare the development of representative live bacterial vectors, and summarize the main characterizations of the various delivery strategies of heterologous antigen in live vector vaccines.

Introduction

An ideal vaccine vector should not only enable trigger potent innate but also adaptive immune responses in inoculated host. Using live bacterial as vector to deliver heterologous antigen is an effective and original alternative for developing a new vaccine. The immunostimulatory capacity of live microorganisms makes it extremely efficient system for induction of long-term and specific immune responses against heterologous antigens. Besides expression and delivery of target antigens, the natural properties of these live microorganisms enable them to act as effective immune adjuvants. For example, the characteristic about intracellular transmission of Listeria monocytogenes (Lm) make this microorganism uniquely suitable for processing as a live bacterial vaccine vector to induce cellular immunologic response against infectious diseases and cancer [1]; the intestinal adhesion of lactic acid bacteria (LAB) play a key role in producing bioactive metabolites to maintain gastrointestinal ecological balance [2].

Although there are many advantages involved in viewing live bacterial as an alternative system for the delivery of heterologous molecules applications, certain problems must also be resolved before the use of these live microorganisms can be applied in the field. There are many safe issues regarding the use of live bacterial and their potential release for human consumption, such the risk of genetically modified organisms (GMOs) persistence in the host and environment. However, preclinical results supporting potential risks of live bacterial vaccine are predictable, and current strategies to delivery heterologous antigen are diversified, such as bacterial surface display system, bacterial secretion system and balanced lethal vector system. The form of immunogen expression and delivery has a crucial impact on the quality and level of the immune response of the inoculated host. Hence, we should select suitable bacterial vaccine vector and corresponding heterologous antigen delivery system according to different diseases. This review attempts to compare the development of representative live bacterial vectors, and summarize the main characterizations of the various delivery strategies of heterologous antigen in live bacterial vector. Because our review had to be brief, we apologize for not being able to provide a more detailed analysis for all live bacterial vaccine vectors.

Section snippets

Attenuated bacteria as live vaccine vector

William Coley first found that tumor was regressed after the injection of killed bacteria directly in 1893 [[3], [4]]. With the development of immunology, both of cellular and humoral immune response could be stimulated by inoculation of attenuated bacteria to protect host against challenge of corresponding wild pathogens. Further, live-attenuated bacteria, carrying heterologous antigens, are also promising combination vaccine vectors to induce effective immune-mediated protection against other

Lactic acid bacteria (LAB) as mucosal delivery vehicles

Although live-attenuated bacterial is a powerful adjuvant, the certain limitations, such as risk of reversion, and imbalance between immunogenicity and side effects, must also be taken into account. LAB are non-pathogenic, they can overcome some of the limitations of live-attenuated bacteria vaccine vector and are attractive alternative to attenuated bacteria. Moreover, LAB are good candidates for the development of oral vaccines and satisfy the requirements of delivery systems for mucosal

Delivery strategies of heterologous antigen in live bacterial

The form of heterologous antigen expression has a crucial impact on the type and efficiency of immune response of live bacterial vaccine. In most experiments, heterologous antigens are fused into bacterial host by plasmid. However, heterologous proteins expressed from genome site-specific integration are more stable than those expressed by plasmids. Most recombinant plasmids display stability in vitro under antibiotic selective pressure, the plasmid-bearing vaccine strain often degenerates

Conclusions and future directions

Over the past two decades, the research of live bacterial vaccines has shown inspiring progress. A number of live bacterial vectors are proved to be effective tools for application in the field of biotherapy, some of which are currently evaluated in clinical trials. New bacterial vectors, expression strategies of heterologous antigen and immunization routes have significantly raised the feasibility of vaccines based on live bacterial vector platform. In parallel with the development of live

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Conflict of interest

The authors declare that they have no conflict of interest.

Acknowledgments

This study was supported by grants from the Natural Science Foundation of China (NO. 31371776), the Agricultural Science Promotion Plan of Shanghai (2017, NO. 4-4) and the Science and Technology Innovation Plan of Shanghai: Yangtze River Delta Joint Research (NO. 15395810900).

References (97)

  • R.M. Salazar-Gonzalez et al.

    CCR6-mediated dendritic cell activation of pathogen-specific T cells in Peyer's patches

    Immunity

    (2006)
  • J. Tobias et al.

    Surface expression of Helicobacter pylori HpaA adhesion antigen on Vibrio cholerae, enhanced by co-expressed enterotoxigenic Escherichia coli fimbrial antigens

    Microb. Pathog.

    (2017)
  • Y. Gao et al.

    A live attenuated combination vaccine evokes effective immune-mediated protection against Edwardsiella tarda and Vibrio anguillarum

    Vaccine

    (2014)
  • A.J. Macpherson et al.

    The bilateral responsiveness between intestinal microbes and IgA

    Trends Immunol.

    (2015)
  • Y. Yan et al.

    Asd-based balanced-lethal system in attenuated Edwardsiella tarda to express a heterologous antigen for a multivalent bacterial vaccine

    Fish Shellfish Immunol.

    (2013)
  • J.E. Galan et al.

    Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains

    Gene

    (1990)
  • F. Duong et al.

    Biogenesis of the gram-negative bacterial envelope

    Cell

    (1997)
  • X. Zhang et al.

    Heterologous expression of carcinoembryonic antigen in Lactococcus lactis via LcsB-mediated surface displaying system for oral vaccine development

    J. Microbiol. Immunol. Infect. Wei mian yu gan ran za zhi

    (2016)
  • S.H.E. Kaufmann et al.

    Impact of intracellular location of and antigen display by intracellular bacteria: implications for vaccine development

    Immunol. Lett.

    (1999)
  • A.R. Bernard et al.

    Detergent isolation stabilizes and activates the shigella type III secretion system translocator protein IpaC

    J. Pharm. Sci.

    (2016)
  • M.J. Pallen

    The ESAT-6/WXG100 superfamily − and a new Gram-positive secretion system

    Trends Microbiol.

    (2002)
  • A. Naz et al.

    Identification of putative vaccine candidates against Helicobacter pylori exploiting exoproteome and secretome: a reverse vaccinology based approach

    Infect. Genet. Evol.

    (2015)
  • G. Sciaranghella et al.

    A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly

    Vaccine

    (2011)
  • D. Bumann et al.

    Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers

    Vaccine

    (2010)
  • S.U. Seo et al.

    Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice

    Vaccine

    (2012)
  • L. Wang et al.

    Oral vaccination with attenuated salmonella typhimurium-delivered TsPmy DNA vaccine elicits protective immunity against trichinella spiralis in BALB/c mice

    Plos Negl. Trop. Dis.

    (2016)
  • L.J. Hall et al.

    Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein

    Vaccine

    (2009)
  • X. Chauchet et al.

    Poly-functional and long-lasting anticancer immune response elicited by a safe attenuated Pseudomonas aeruginosa vector for antigens delivery

    Mol. Ther. Oncolytics

    (2016)
  • Y. Tsukamoto et al.

    Enhanced protective efficacy against tuberculosis provided by a recombinant urease deficient BCG expressing heat shock protein 70-major membrane protein-II having PEST sequence

    Vaccine

    (2016)
  • R. Li et al.

    Mucosally administered Lactobacillus surface-displayed influenza antigens (sM2 and HA2) with cholera toxin subunit A1 (CTA1) Induce broadly protective immune responses against divergent influenza subtypes

    Vet. Microbiol.

    (2015)
  • S.H. Shi et al.

    Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection

    Virus Res.

    (2016)
  • W.T. Yang et al.

    Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum

    Antiviral Res.

    (2017)
  • F.N. Liu et al.

    Dual functions of lactobacillus acidophilus NCFM as protection against rotavirus diarrhea

    J. Pediatr. Gastroenterol. Nutr.

    (2014)
  • G. Gunaydin et al.

    Engineered Lactobacillus rhamnosus GG expressing IgG-binding domains of protein G: capture of hyperimmune bovine colostrum antibodies and protection against diarrhea in a mouse pup rotavirus infection model

    Vaccine

    (2014)
  • T.R. Veloso et al.

    Vaccination against Staphylococcus aureus experimental endocarditis using recombinant Lactococcus lactis expressing ClfA or FnbpA

    Vaccine

    (2015)
  • C. Daniel et al.

    Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis

    Vaccine

    (2016)
  • J.Y. Yao et al.

    Live recombinant Lactococcus lactis vaccine expressing immobilization antigen (i-Ag) for protection against Ichthyophthirius multifiliis in goldfish

    Fish Shellfish Immunol.

    (2016)
  • M. Wang et al.

    Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option

    Appl. Microbiol. Biotechnol.

    (2016)
  • B. Toussaint et al.

    Live-attenuated bacteria as a cancer vaccine vector

    Expert Rev. Vaccines

    (2013)
  • W.B. Coley

    The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893

    Clin. Orthop.

    (1991)
  • D.G. Brockstedt et al.

    Clinical experience with live-attenuated, double-deleted (LADD) listeria monocytogenes targeting mesothelin-expressing tumors

    J. Immunother. Cancer

    (2013)
  • P.V. Johnson et al.

    Attenuated Listeria monocytogenes vaccine vectors expressing Influenza A nucleoprotein: preclinical evaluation and oral inoculation of volunteers

    Microbiol. Immunol.

    (2011)
  • E.L. Hohmann et al.

    phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers

    J. Infect. Dis.

    (1996)
  • W. Mustafa et al.

    Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-Mediated CD4(+) and CD8(+) T-Cell responses after oral immunization

    Viral Immunol.

    (2009)
  • I.J. Glomski et al.

    Listeria monocytogenes mutants that fail to compartmentalize listerolysin O activity are cytotoxic, avirulent, and unable to evade host extracellular defenses

    Infect. Immun.

    (2003)
  • C. Wang et al.

    Expression of porcine respiratory and reproductive syndrome virus membrane-associated proteins in Listeria ivanovii via a genome site-specific integration and expression system

    J. Mol. Microbiol. Biotechnol.

    (2014)
  • M.N. Dharmasena et al.

    Development of an acid-resistant salmonella typhi ty21a attenuated vector for improved oral vaccine delivery

    PLoS One

    (2016)
  • J.E. Galen et al.

    Live attenuated human salmonella vaccine candidates: tracking the pathogen in natural infection and stimulation of host immunity

    EcoSal Plus

    (2016)
  • Cited by (0)

    View full text